Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | PER2 | O15055 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080578 | 0.77 | DRD2 (0.48) | HDAC1DRD2DRD3KCNH2RAB9A | |
| SCHEMBL20912151 | 0.77 | FFAR1 (0.44) | HDAC1SCN9ADRD2DRD3KCNH2 | |
| SCHEMBL31317662 | 0.75 | SCN9A (0.39) | SCN9APER2 | |
| SCHEMBL20911963 | 0.73 | DRD2 (0.48) | HDAC1DRD2DRD3KCNH2RAB9A | |
| SCHEMBL29348992 | 0.73 | PER2 (0.41) | HDAC1DRD2DRD3RAB9ACYP1A1 | |
| SCHEMBL22582347 | 0.72 | DRD2 (0.42) | HDAC1DRD2DRD3KCNH2RAB9A | |
| SCHEMBL16915090 | 0.72 | HDAC1 (0.67) | HDAC1DRD2DRD3RAB9A | |
| SCHEMBL1207386 | 0.72 | RAB9A (0.37) | HDAC1DRD2DRD3KCNH2RAB9A | |
| SCHEMBL20911964 | 0.71 | DRD2 (0.46) | HDAC1DRD2DRD3KCNH2RAB9A | |
| SCHEMBL19297530 | 0.71 | RAB9A (0.45) | HDAC1DRD2DRD3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20200339583-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
| WO-2019073253-A1 | MAP4K4 INHIBITORS | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339583-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | HDAC1 2049/4885SCN9A 4339/4885DRD2 4784/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | HDAC1 2049/4885SCN9A 4339/4885DRD2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.